Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Gyros AB Appoints Dr Henrik Björkman as CTO and VP Technical Affairs

Published: Monday, January 21, 2013
Last Updated: Monday, January 21, 2013
Bookmark and Share
Dr Henrik Björkman will lead the R&D and product supply teams.

As part of his new role at Gyros, Henrik will have responsibility for driving strategic and operational decisions, managing product development, intellectual property, manufacturing, QA, and QC, and will oversee the existing product range. As part of the executive management team Henrik will work closely with marketing and sales departments, reporting to the board of directors.

Henrik joins Gyros from GE Healthcare Life Sciences, where he was most recently Director, MicroCal R&D, leading the MicroCal operation in Northampton, MA. He has many years of experience in senior positions within R&D, technical and management roles, at a range of life science companies from small organizations to larger, industrial enterprises. Henrik holds a PhD in Materials Science and Micro Engineering from Uppsala University.

“The technology developed at Gyros offers an exciting step forward for the biopharmaceutical community,” said Henrik. “I am excited to have the opportunity to support the continued success of the Gyros immunoassay platform.”

Erik Walldén, CEO at Gyros, commented: “We welcome Henrik to Gyros, and look forward to working with him. Bringing extensive experience in product development and manufacturing for globalized, commercial organizations in the life science tools industry, Henrik will be a great asset for the continued development of our microfluidic immunoassay technology.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Gyros AB, Protein Technologies Merge
Merger creates fast growing, global provider of sample prep, synthesis and bioanalytical tools for biotherapeutics discovery, development and manufacturing
Wednesday, March 16, 2016
Gyros and Tekon Biotech Sign Distribution Agreement
Tekon will distribute Gyros’ immunoassay platform in China, Taiwan & Hong Kong.
Tuesday, April 01, 2014
Gyros and GE Healthcare Life Sciences Expand Asian Distribution Relationship
Gyros AB announces that GE Healthcare Life Sciences has become sole distributor for the company’s nanoliter-scale immunoassay platform in China, Taiwan and Hong Kong.
Friday, August 26, 2011
Gyros and GE Healthcare Life Sciences Sign Distribution Agreement
Gyros AB announces that GE Healthcare Life Sciences has become the sole distributor for the company’s nanoliter-scale immunoassay platform in Japan.
Tuesday, July 12, 2011
Scientific News
Breakthrough Flu Vaccine Inhibited by Pre-existing Antibodies
Universal truths – how existing antibodies are sabotaging the most promising new human flu vaccines.
Zika Vaccine Candidates Show Promise
Two experimental vaccines have shown promise against a major viral strain responsible for the Brazilian Zika outbreak.
NIH Begins Yellow Fever Vaccine Trial
NIH has initiated an early-stage clinical trial of a vaccine to protect against yellow fever.
Antibody Drug Shows Promise in HIV Treatment
Researchers are a step closer to an alternative HIV treatment that has the potential for lasting effects and less frequent dosing.
Flu Vaccine May Reduce Risk of Death For Type 2 Diabetes Patients
Researchers at Imperial College London have suggested that the vaccine may have substantial benefits for patients with long-term conditions.
Flu Vaccine May Reduce Death Risk of Type 2 Diabetes
New research suggests that a new flu vaccine may reduce probability of type 2 diabetes patients being hospitalised with stroke and heart failure.
Disrupting Tumour-Promotion in Humans
Researchers have modified an existing protein to represses a specific cancer-promoting ‘message’ within cells.
Protein Nanocages Could Improve Drug Design and Delivery
HHMI scientists have designed and built 10 large protein icosahedra that are similar to viral capsids that carry viral DNA.
Vaccine Strategy Targets Multiple Influenza Viruses
Scientists have identified vaccine-induced antibodies that can neutralize strains of influenza virus that infect humans.
Antibody-Based Drug for Multiple Sclerosis
New antibody-based drug paves the way for new strategies for controlling and treating multiple sclerosis.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!